OBJECTIVE: To observe the dynamic changes of blood perfusion and hypoxic status with CT perfusion imaging and hypoxia imaging in patients of non-small-cell lung cancer (NSCLC) who were treated withrecombinant human endostatin (RHES). METHODS:Fifteen previously untreated patients with histologically or cytologically confirmed NSCLC were enrolled. They were randomly divided into research group (n=10) and negative control group (n=5). The patients of the research group continuously used RHES for ten days, and simultaneously had CT perfusion imaging and hypoxia imaging performed on days 1, 5 and 10, respectively. The remaining 5(control) only had CT perfusion imaging and hypoxia imaging, without using RHES, on days 1, 5 and 10, respectively. According to the above results, we could obtain a "time window" during which RHES improves blood perfusion and hypoxia of lung cancer. RESULTS: In the research group, after using RHES, capillary permeability surface (PS) and tumour to normal tissue (T/N) decreased at first, and then increased. Their lowest points occurred on about the fifth day with statistical significance compared with the first day (T/N, p=0.00; PS, p<0.01). Blood flow (BF) was first increased and then decreased. Its highest point occurred on about the fifth day with statistical significance compared with the first and tenth day (all p<0.01). The PS, BF and T/N peaked on the fifth day in the research group with statistical significance compared with the negative control group as well (all p<0.01). The above results suggested that RHES's "time window" was within about one week after administration. CONCLUSION:RHES's "time window" is within about one week after administration, which provides an important experimental basis for combining RHES with radiotherapy in human tumours.
RCT Entities:
OBJECTIVE: To observe the dynamic changes of blood perfusion and hypoxic status with CT perfusion imaging and hypoxia imaging in patients of non-small-cell lung cancer (NSCLC) who were treated with recombinant humanendostatin (RHES). METHODS: Fifteen previously untreated patients with histologically or cytologically confirmed NSCLC were enrolled. They were randomly divided into research group (n=10) and negative control group (n=5). The patients of the research group continuously used RHES for ten days, and simultaneously had CT perfusion imaging and hypoxia imaging performed on days 1, 5 and 10, respectively. The remaining 5(control) only had CT perfusion imaging and hypoxia imaging, without using RHES, on days 1, 5 and 10, respectively. According to the above results, we could obtain a "time window" during which RHES improves blood perfusion and hypoxia of lung cancer. RESULTS: In the research group, after using RHES, capillary permeability surface (PS) and tumour to normal tissue (T/N) decreased at first, and then increased. Their lowest points occurred on about the fifth day with statistical significance compared with the first day (T/N, p=0.00; PS, p<0.01). Blood flow (BF) was first increased and then decreased. Its highest point occurred on about the fifth day with statistical significance compared with the first and tenth day (all p<0.01). The PS, BF and T/N peaked on the fifth day in the research group with statistical significance compared with the negative control group as well (all p<0.01). The above results suggested that RHES's "time window" was within about one week after administration. CONCLUSION:RHES's "time window" is within about one week after administration, which provides an important experimental basis for combining RHES with radiotherapy in humantumours.
Authors: Xian Luo; Melba L Andres; Tatyana M Timiryasova; Istvan Fodor; James M Slater; Daila S Gridley Journal: Technol Cancer Res Treat Date: 2005-04
Authors: Tracy T Batchelor; A Gregory Sorensen; Emmanuelle di Tomaso; Wei-Ting Zhang; Dan G Duda; Kenneth S Cohen; Kevin R Kozak; Daniel P Cahill; Poe-Jou Chen; Mingwang Zhu; Marek Ancukiewicz; Maciej M Mrugala; Scott Plotkin; Jan Drappatz; David N Louis; Percy Ivy; David T Scadden; Thomas Benner; Jay S Loeffler; Patrick Y Wen; Rakesh K Jain Journal: Cancer Cell Date: 2007-01 Impact factor: 31.743
Authors: Chun-hua Ling; Cheng Ji; Yan-bin Chen; Jian-xin Fu; Ju-ying Zhou; Wei-chang Chen; Ji-cheng Yang; Liao-yuan Su Journal: Zhonghua Jie He He Hu Xi Za Zhi Date: 2004-10
Authors: Frank Winkler; Sergey V Kozin; Ricky T Tong; Sung-Suk Chae; Michael F Booth; Igor Garkavtsev; Lei Xu; Daniel J Hicklin; Dai Fukumura; Emmanuelle di Tomaso; Lance L Munn; Rakesh K Jain Journal: Cancer Cell Date: 2004-12 Impact factor: 31.743
Authors: Ruud P M Dings; Melissa Loren; Hanke Heun; Elizabeth McNiel; Arjan W Griffioen; Kevin H Mayo; Robert J Griffin Journal: Clin Cancer Res Date: 2007-06-01 Impact factor: 12.531
Authors: Louise S Strauch; Rie Ø Eriksen; Michael Sandgaard; Thomas S Kristensen; Michael B Nielsen; Carsten A Lauridsen Journal: Diagnostics (Basel) Date: 2016-07-21